Treatment Information

Back

Rectal Cancer treatment details. Chemotherapy.

La Paz, Madrid, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:5City/State/Province:Madrid
Treatments:ChemotherapyHospital:La Paz
Drugs:Journal:Link
Date:Nov 2005

Description:

Patients: This Phase II study involved 94 patients with untreated advanced colorectal cancer. Metastatic sites included lung, liver, and "abdominopelvis mass". 58 patients had colon cancer and 36 patients had rectal cancer. The patients were randomly assigned into two groups. Group A had 48 patients (28 men, 20 women) with a median age of 63 years. Group B had 46 patients (31 men, 15 women) with a median age of 63 years.

Treatment: For Group A, treatment consisted of two chemotherapeutic agents: raltitrexed and oxaliplatin.

For Group B, treatment consisted of two chemotherapeutic agents: raltitrexed and irinotecan.

Toxicity: For Group A, one patient died during the study; other grade 3-4 toxicities included nausea/vomiting, peripheral neuropathy, elevated liver enzymes, diarrhea, and asthenia.

For Group B, three patients died during the study; other grade 3-4 toxicities included diarrhea, elevated liver enzymes, neutropenia, asthenia, and nausea/vomiting.

Results: The median overall survival was not reported. The overall response rate for Group A was 46% (4 complete responses, 18 partial responses) with 12 patients with stable disease. The overall response rate fo Group B was 34% (2 complete responses, 14 partial responses) with 15 patients with stable disease.

Correspondence: Dr. J. Feliu




Back